Research Article27th Philip Kittredge Memorial Lecture

Myths, Misunderstandings, and Dogma in Respiratory Care

Bruce K Rubin and Jeffrey M Haynes
Respiratory Care August 2012, 57 (8) 1314-1324; DOI: https://doi.org/10.4187/respcare.01816

References

  1. 1.↵
    1. Isaacs D,
    2. Fitzgerald D
    . Seven alternatives to evidenced based medicine. BMJ 1999;319(7225):1618.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Giles TL,
    2. Lasserson TJ,
    3. Smith BH,
    4. White J,
    5. Wright J,
    6. Cates CJ
    . Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006;(3):CD001106.
  3. 3.↵
    1. Brochard L,
    2. Mancebo J,
    3. Wysocki M,
    4. Lofaso F,
    5. Conti G,
    6. Rauss A,
    7. et al
    . Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995;333(13):817–822.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Kittredge P
    . Continuous positive airway pressure via face mask is a dangerous step backwards. Chest 1977;71(1)118–119.
    OpenUrlPubMed
  5. 5.↵
    1. Dolovich MB,
    2. Killian D,
    3. Wolff RK,
    4. Obminski G,
    5. Newhouse MT
    . Pulmonary aerosol deposition in chronic bronchitis: intermittent positive pressure breathing versus quiet breathing. Am Rev Respir Dis 1977;115(3):397–402.
    OpenUrlPubMedWeb of Science
  6. 6.↵
    1. Ranieri VM,
    2. Dambrosio M,
    3. Brienza N
    . Intrinsic PEEP and cardiopulmonary interaction in patients with COPD and acute ventilatory failure. Eur Respir J 1996;9(6):1283–1292.
    OpenUrlAbstract
  7. 7.↵
    1. Moore M,
    2. Little P
    . Humidified air inhalation for treating croup. Cochrane Database Syst Rev 2006;(3):CD002870.
  8. 8.↵
    1. Scolnik D,
    2. Coates AL,
    3. Stephens D,
    4. Da Silva Z,
    5. Lavine E,
    6. Schuh S
    . Controlled delivery of high vs low humidity vs mist therapy for croup in emergency departments: a randomized controlled trial. JAMA 2006;295(11):1274–1280.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Rosenbluth M,
    2. Chernick V
    . Influence of mist tent therapy on sputum viscosity and water content in cystic fibrosis. Are Dis Child 1974;49(8):606–610.
    OpenUrl
  10. 10.↵
    1. Bureau MA,
    2. McDougall DM,
    3. Beaudry PH,
    4. Belmonte MM
    . Late effect of nocturnal mist tent therapy related to the severity of airway obstruction in children with cystic fibrosis. Pediatrics 1978;61(6):842–846.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Jakobsson B,
    2. Hjelte L,
    3. Nyström B
    . Low level of bacterial contamination of mist tents used in home treatment of cystic fibrosis patients. J Hosp Infect 2000;44(1):37–41.
    OpenUrlPubMed
  12. 12.↵
    1. Snydman DR,
    2. Maloy MF,
    3. Brock SM,
    4. Lyons RW,
    5. Rubin SJ
    . Pseudobacteremia: false-positive blood cultures from mist tent contamination. Am J Epidemiol 1977;106(2):154–159.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342(18):1301–1308.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Petty TL,
    2. Newman JH
    . Adult respiratory distress syndrome. West J Med 1978;128(5):399–407.
    OpenUrlPubMedWeb of Science
  15. 15.↵
    1. Hopewell PC
    . Adult respiratory distress syndrome, what to do until the basic scientist comes (editorial). West J Med 1978;128(5):435–436.
    OpenUrlPubMed
  16. 16.↵
    1. Webb HH,
    2. Tierney DF
    . Experimental pulmonary edema due to intermittent positive pressure ventilation with high inflation pressures. Protection by positive end-expiratory pressure. Am Rev Respir Dis 1974;110(5):556–565.
    OpenUrlPubMedWeb of Science
  17. 17.↵
    1. de Prost N,
    2. Ricard JD,
    3. Saumon G,
    4. Dreyfuss D
    . Ventilator-induced lung injury: historical perspectives and clinical applications. Ann Intensive Care 2011;1(1):28.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Hickling KG,
    2. Walsh J,
    3. Henderson S,
    4. Jackson R
    . Low mortality rate in adult respiratory distress syndrome using low-volume, pressure-limited ventilation with permissive hypercapnia: a prospective study. Crit Care Med 1994;22(10):1568–1578.
    OpenUrlPubMedWeb of Science
  19. 19.↵
    1. Amato MB,
    2. Barbas CS,
    3. Medeiros DM,
    4. Magaldi RB,
    5. Schettino GP,
    6. Lorenzi-Filho G,
    7. et al
    . Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998;338(6):347–354.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Bennett S,
    2. Hurford WE
    . When should sedation or neuromuscular blockade be used during mechanical ventilation? Respir Care 2011;56(2):168–176.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Moons P,
    2. Sels K,
    3. De Becker W,
    4. De Geest S,
    5. Ferdinande P
    . Development of a risk assessment tool for deliberate self-extubation in intensive care patients. Intensive Care Med 2004;30(7):1348–1355.
    OpenUrlPubMedWeb of Science
  22. 22.↵
    1. Chevron V,
    2. Ménard JF,
    3. Richard JC,
    4. Girault C,
    5. Leroy J,
    6. Bonmarchand G
    . Unplanned extubation: risk factors of development and predictive criteria for reintubation. Crit Care Med 1998;26(6):1049–1053.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Kollef MH,
    2. Levy NT,
    3. Ahrens TS,
    4. Schaiff R,
    5. Prentice D,
    6. Sherman G
    . The use of continuous intravenous sedation is associated with prolongation of mechanical ventilation. Chest 1998;114(2):541–548.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.
    1. Pandharipande P,
    2. Shintani A,
    3. Peterson J,
    4. Pun BT,
    5. Wilkinson GR,
    6. Dittus RS,
    7. et al
    . Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 2006;104(1):21–26.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Pun BT,
    2. Ely EW
    . The importance of diagnosing and managing ICU delirium. Chest 2007;132(2):624–636.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Rubin BK
    . Mucolytics, expectorants, and mucokinetic medications. Respir Care 2007;52(7):859–865.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Maayan C,
    2. Bar-Yishay E,
    3. Yaacobi T,
    4. Marcus Y,
    5. Katznelson D,
    6. Yahav Y,
    7. Godfrey S
    . Immediate effect of various treatments on lung function in infants with cystic fibrosis. Respiration 1989;55(3):144–151.
    OpenUrlPubMed
  28. 28.↵
    1. Mallet P,
    2. Mourdi N,
    3. Dubus JC,
    4. Bavoux F,
    5. Boyer-Gervoise MJ,
    6. Jean-Pastor MJ,
    7. Chalumeau M
    . Respiratory paradoxical adverse drug reactions associated with acetylcysteine and carbocysteine systemic use in paediatric patients: a national survey. PLoS One 2011;6(7):e22792.
    OpenUrlPubMed
  29. 29.↵
    1. Reinero CR,
    2. Lee-Fowler TM,
    3. Dodam JR,
    4. Cohn LA,
    5. DeClue AE,
    6. Guntur VP
    . Endotracheal nebulization of N-acetylcysteine increases airway resistance in cats with experimental asthma. J Feline Med Surg 2011;13(2):69–73.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. De Benedetto F,
    2. Aceto A,
    3. Dragani B,
    4. Spacone A,
    5. Formisano S,
    6. Pela R,
    7. et al
    . Long-term oral n-acetylcystein reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther 2005;18(1):41–47.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Rysz J,
    2. Stolarek RA,
    3. Luczynski R,
    4. Samiak A,
    5. Wlodarczyk A,
    6. Kasielski M,
    7. Nowak D
    . Increased hydrogen peroxide concentration in the exhaled breath condensate of stable COPD patients after nebulized N-acetylcysteine. Pulm Pharmacol Ther 2007;20(3):281–289.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Neergaard L
    . As drug shortages rise, hospitals hunt for substitutes. Huffington Post, May 30, 2011. http://www.huffingtonpost.com/2011/05/30/drug-shortages-rise_n_868778.html. Accessed May 18, 2012.
  33. 33.↵
    1. King DK,
    2. Thompson BT,
    3. Johnson DC
    . Wheezing on maximal forced exhalation in the diagnosis of atypical asthma. Lack of sensitivity and specificity. Ann Intern Med 1989;110(6):451–455.
    OpenUrlPubMedWeb of Science
  34. 34.↵
    1. Elphick HE,
    2. Lancaster GA,
    3. Solis A,
    4. Majumdar A,
    5. Gupta R,
    6. Smyth RL
    . Validity and reliability of acoustic analysis of respiratory sounds in infants. Arch Dis Child 2004;89(11):1059–1063.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Koh YY,
    2. Kang H,
    3. Yoo Y,
    4. Kim do K,
    5. Yu J,
    6. Kim CK
    . Wheeze detection as a measure of bronchial challenge in young children with cough-variant asthma and with classic asthma. Acta Paediatr 2007;96(8):1223–1227.
    OpenUrlPubMed
  36. 36.↵
    1. Wilson NM,
    2. Bridge P,
    3. Phagoo SB,
    4. Silverman M
    . The measurement of methacholine responsiveness in 5-year-old children: three methods compared. Eur Respir J 1995;8(3):364–370.
    OpenUrlAbstract
  37. 37.↵
    1. Teeter JG,
    2. Bleecker ER
    . Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest 1998;113(2):272–277.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Jones AP,
    2. Wallis C
    . Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 2010;(3):CD001127.
  39. 39.↵
    1. Rubin BK
    . Who will benefit from DNase? Pediatr Pulmonol 1999;27(1):3–4.
    OpenUrlPubMed
  40. 40.↵
    1. Smyth AR,
    2. Barbato A,
    3. Beydon N,
    4. Bisgaard H,
    5. de Boeck K,
    6. Brand P,
    7. et al
    . Respiratory medicines for children: current evidence, unlicensed use and research priorities. Eur Respir J 2010;35(2):247–265.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Murakami G,
    2. Igarashi T,
    3. Adachi Y,
    4. Matsuno M,
    5. Adachi Y,
    6. Sawai M,
    7. et al
    . Measurement of bronchial hyperreactivity in infants and preschool children using a new method. Ann Allergy 1990;64(4):383–387.
    OpenUrlPubMedWeb of Science
  42. 42.
    1. Everard ML,
    2. Clark AR,
    3. Milner AD
    . Drug delivery from jet nebulisers. Arch Dis Child 1992;67(5):586–591.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Smaldone GC,
    2. Berg E,
    3. Nikander K
    . Variation in pediatric aerosol delivery: importance of facemask. J Aerosol Med 2005;18(3):354–363.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Panitch HB,
    2. Keklikian EN,
    3. Motley RA,
    4. Wolfson MR,
    5. Schidlow DV
    . Effect of altering smooth muscle tone on maximal expiratory flows in patients with tracheomalacia. Pediatr Pulmonol 1990;9(3):170–176.
    OpenUrlPubMedWeb of Science
  45. 45.↵
    Revised product labels for pediatric over-the-counter cough and cold medicines. MMWR Morb Mortal Wkly Rep 2008;57(43):1180.
    OpenUrlPubMed
  46. 46.↵
    1. Gunn VL,
    2. Taha SH,
    3. Liebelt EL,
    4. Serwint JR
    . Toxicity of over-the-counter cough and cold medications. Pediatrics 2001;108(3):E52.
    OpenUrlCrossRefPubMed
  47. 47.
    1. Dart RC,
    2. Paul IM,
    3. Bond GR,
    4. Winston DC,
    5. Manoguerra AS,
    6. Palmer RB,
    7. Kauffman RE,
    8. Banner W,
    9. Green JL,
    10. Rumack BH
    . Pediatric fatalities associated with over the counter (nonprescription) cough and cold medications. Ann Emerg Med 2009;53(4):411–417.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    1. Rimsza ME,
    2. Newberry S
    . Unexpected infant deaths associated with use of cough and cold medications. Pediatrics 2008;122(2):e318–322.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    1. Eccles R
    . The powerful placebo in cough studies? Pharmacol Ther 2002;15(3):303–308.
    OpenUrl
  50. 50.↵
    1. Hutton N,
    2. Wilson MH,
    3. Mellits ED,
    4. Baumgardner R,
    5. Wissow LS,
    6. Bonuccelli C,
    7. et al
    . Effectiveness of an antihistamine-decongestant combination for young children with the common cold: a randomized, controlled clinical trial. J Pediatr 1991;118(1):125–130.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.↵
    1. Vassilev ZP,
    2. Kabadi S,
    3. Villa R
    . Safety and efficacy of over-the-counter cough and cold medicines for use in children. Expert Opin Drug Saf 2010;9(2):233–242.
    OpenUrlCrossRefPubMedWeb of Science
  52. 52.↵
    1. Stein RT,
    2. Holberg CJ,
    3. Morgan WJ,
    4. Wright AL,
    5. Lombardi E,
    6. Taussig L,
    7. Martinez FD
    . Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhood. Thorax 1997;52(11):946–952.
    OpenUrlAbstract
  53. 53.↵
    1. Martinez FD
    . Development of wheezing disorders and asthma in preschool children. Pediatrics 2002;109(2 Suppl):362–367.
    OpenUrlPubMedWeb of Science
  54. 54.↵
    1. Martinez FD,
    2. Morgan WJ,
    3. Wright AL,
    4. Holberg CJ,
    5. Taussig LM
    . Diminished lung function as a predisposing factor for wheezing respiratory illness in infants. N Engl J Med 1988;319(17):1112–1117.
    OpenUrlCrossRefPubMedWeb of Science
  55. 55.↵
    1. Tager IB,
    2. Hanrahan JP,
    3. Tosteson TD,
    4. Castile RG,
    5. Brown RW,
    6. Weiss ST,
    7. Speizer FE
    . Lung function, pre- and post-natal smoke exposure, and wheezing in the first year of life. Am J Respir Crit Care Med 1993;147(4):811–817.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Young S,
    2. O'Keeffe PT,
    3. Arnott J,
    4. Landau LI
    . Lung function, airway responsiveness, and respiratory symptoms before and after bronchiolitis. Arch Dis Child 1995;72(1):16–24.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Stevenson EC,
    2. Turner G,
    3. Heaney LG,
    4. Schock BC,
    5. Taylor R,
    6. Gallagher T,
    7. et al
    . Bronchoalveolar lavage findings suggest two different forms of childhood asthma. Clin Exp Allergy 1997;27(9):1027–1035.
    OpenUrlCrossRefPubMedWeb of Science
  58. 58.↵
    1. Oswald H,
    2. Phelan PD,
    3. Lanigan A,
    4. Hibbert M,
    5. Carlin JB,
    6. Bowes G,
    7. Olinsky A
    . Childhood asthma and lung function in mid-adult life. Pediatr Pulmonol 1997;23(1):14–20.
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.↵
    1. Marchant JM,
    2. Masters IB,
    3. Taylor SM,
    4. Cox NC,
    5. Seymour GJ,
    6. Chang AB
    . Evaluation and outcome of young children with chronic cough. Chest 2006;129(5):1132–1141.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    1. Chang AB,
    2. Phelan PD,
    3. Carlin JB,
    4. Sawyer SM,
    5. Robertson CF
    . A randomized, placebo controlled trial of inhaled salbutamol and beclomethasone for recurrent cough. Arch Dis Child 1998;79(1):6–11.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Abu-Hasan M,
    2. Tannous B,
    3. Weinberger M
    . Exercise-induced dyspnea in children and adolescents: if not asthma then what? Ann Allergy Asthma Immunol 2005;94(3):366–371.
    OpenUrlPubMedWeb of Science
  62. 62.↵
    1. Weinberger M,
    2. Abu-Hasan M
    . Pseudo-asthma: When cough, wheezing, and dyspnea are not asthma. Pediatrics 2007;120(4):855–864.
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Lötvall J,
    2. Palmqvist M,
    3. Arvidsson P,
    4. Maloney A,
    5. Ventresca GP,
    6. Ward J
    . The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001;108(5):726–731.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.
    1. Mansfield P,
    2. Henry D,
    3. Tonkin A
    . Single-enantiomer drugs: elegant science, disappointing effects. Clin Pharmacokinet 2004;43(5):287–290.
    OpenUrlCrossRefPubMedWeb of Science
  65. 65.
    1. Patel M,
    2. Thomson NC
    . (R)-salbutamol in the treatment of asthma and chronic obstructive airways disease. Expert Opin Pharmacother 2011;12(7):1133–1141.
    OpenUrlPubMed
  66. 66.
    1. Wilkinson M,
    2. Bulloch B,
    3. Garcia-Filion P,
    4. Keahey L
    . Efficacy of racemic albuterol versus levalbuterol used as a continuous nebulization for the treatment of acute asthma exacerbations: a randomized, double-blind, clinical trial. J Asthma 2011;48(2):188–193.
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Andrews T,
    2. McGintee E,
    3. Mittal MK,
    4. Tyler L,
    5. Chew A,
    6. Zhang X,
    7. et al
    . High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial. J Pediatr 2009;155(2):205–210.
    OpenUrlCrossRefPubMed
  68. 68.↵
    1. O'Donnell DE,
    2. Forkert L,
    3. Webb KA
    . Evaluation of bronchodilator responses in patients with “irreversible” emphysema. Eur Respir J 2001;18(6):914–920.
    OpenUrlAbstract/FREE Full Text
  69. 69.↵
    1. Becker JM,
    2. Arora A,
    3. Scarfone RJ,
    4. Spector ND,
    5. Fontana-Penn ME,
    6. Gracely E,
    7. et al
    . Oral versus intravenous corticosteroids in children hospitalized with asthma. J Allergy Clin Immunol 1999;103(4):586–590.
    OpenUrlCrossRefPubMedWeb of Science
  70. 70.↵
    1. Cunnington D,
    2. Smith N,
    3. Steed K,
    4. Rosengarten P,
    5. Kelly AM,
    6. Teichtahl H
    . Oral versus intravenous corticosteroids in adults hospitalised with acute asthma. Pulm Pharmacol Ther 2005;18(3):207–212.
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. de Jong YP,
    2. Uil SM,
    3. Grotjiohan HP,
    4. Postma DS,
    5. Kerstjens HA,
    6. van den Berg JW
    . Oral or i.v. prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest 2007;132(6):1741–1747.
    OpenUrlCrossRefPubMedWeb of Science
  72. 72.↵
    1. Nakanishi AK,
    2. Klasner AK,
    3. Rubin BK
    . A randomized controlled trial of inhaled flunisolide in the management of acute asthma in children. Chest 2003;124(3):790–794.
    OpenUrlCrossRefPubMedWeb of Science
  73. 73.↵
    1. Lee-Wong M,
    2. Dayrit FM,
    3. Kohli AR,
    4. Acquah S,
    5. Mayo PH
    . Comparison of high-dose inhaled flunisolide to systemic corticosteroids in severe adult asthma. Chest 2002;122(4):1208–1213.
    OpenUrlCrossRefPubMed
  74. 74.↵
    1. Beasley R,
    2. Aldington S,
    3. Weatherall M,
    4. Robinson G,
    5. McHaffle D
    . Oxygen therapy in myocardial infarction: an historical perspective. J R Soc Med 2007;100(3):130–133.
    OpenUrlFREE Full Text
  75. 75.↵
    1. McNulty PH,
    2. Robertson BJ,
    3. Tulli MA,
    4. Hess J,
    5. Harach LA,
    6. Scott S,
    7. Sinoway LI
    . Effect of hyperoxia and vitamin C on coronary blood flow in patients with ischemic heart disease. J Appl Physiol 2007;102(5):2040–2045.
    OpenUrlAbstract/FREE Full Text
  76. 76.↵
    1. Winegrad S,
    2. Daniel Henrion,
    3. Rappaport L,
    4. Samuel JL
    . Self-protection by cardiac myocytes against hypoxia and hyperoxia. Circ Res 1999;85(8):690–698.
    OpenUrlAbstract/FREE Full Text
  77. 77.↵
    1. Russek HI,
    2. Regan FD,
    3. Naegele CF
    . One hundred percent oxygen in the treatment of acute myocardial infarction and severe angina pectoris. J Am Med Assoc 1950;144(5):373–375.
    OpenUrlCrossRefPubMedWeb of Science
  78. 78.↵
    1. Rawles JM,
    2. Kenmure AC
    . Controlled trial of oxygen in uncomplicated myocardial infarction. BMJ 1976;1(6018):1121–1123.
    OpenUrlAbstract/FREE Full Text
  79. 79.↵
    1. Cabello JB,
    2. Buris A,
    3. Emparanza JL,
    4. Bayliss S,
    5. Quinn T
    . Oxygen therapy for acute myocardial infarction. Cochrane Database Syst Rev 2010;16(6):CD007160.
    OpenUrl
  80. 80.↵
    1. Miller MR,
    2. Quanjer PH,
    3. Swanney MP,
    4. Ruppel G,
    5. Enright PL
    . Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. Chest 2011;139(1):52–59. Erratum in Chest 2011;139(3):733.
    OpenUrlCrossRefPubMedWeb of Science
  81. 81.↵
    1. Sobol BJ,
    2. Sobol PG
    . Per cent of predicted as the limit of normal in pulmonary function testing: a statistically valid approach (editorial). Thorax. 1979;34(1):1–3.
    OpenUrlFREE Full Text
  82. 82.↵
    1. Swanney MP,
    2. Ruppel G,
    3. Enright PL,
    4. Pedersen OF,
    5. Crapo RO,
    6. Miller MR,
    7. et al
    . Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008;63(12):1046–1051.
    OpenUrlAbstract/FREE Full Text
  83. 83.↵
    1. Hunter WG
    . Six statistical tales. The Statistician 1981;30(2):107–117.
    OpenUrl
  84. 84.↵
    1. Mould RF
    . Introductory medical statistics. Philadelphia: Institute of Physics Publishing; 1998:182.
  85. 85.↵
    1. Porta N,
    2. Bonet C,
    3. Cobo E
    . Discordance between reported intention-to-treat and per protocol analyses. J Clin Epidemiol 2007;60(7):663–669.
    OpenUrlCrossRefPubMedWeb of Science
  86. 86.↵
    1. Akobeng AK
    . Understanding measures of treatment effect in clinical trials. Arch Dis Child 2005;90(1):54–56.
    OpenUrlAbstract/FREE Full Text
  87. 87.↵
    1. Kalhan R,
    2. Mikkelsen M,
    3. Dedhiva P,
    4. Christie J,
    5. Gaughan C,
    6. Finkel B,
    7. et al
    . Underuse of lung protective ventilation: analysis of potential factors to explain physician behavior. Crit Care Med 2006;34(2):300–306.
    OpenUrlCrossRefPubMedWeb of Science
  88. 88.↵
    1. Brunkhorst FM,
    2. Engel C,
    3. Ragaller M,
    4. Welte T,
    5. Rossaint R,
    6. Gerlach H,
    7. et al
    . Practice and perception-a nationwide survey of therapy habits in sepsis. Crit Care Med 2008;36(10):2719–2725.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

 

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Related Articles

Cited By...

Keywords